Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 409

1.

Minimal factor XIII activity level to prevent major spontaneous bleeds.

Menegatti M, Palla R, Boscarino M, Bucciarelli P, Muszbek L, Katona E, Makris M, Peyvandi F; PRO-RBDD study group.

J Thromb Haemost. 2017 Sep;15(9):1728-1736. doi: 10.1111/jth.13772. Epub 2017 Aug 17.

PMID:
28688221
2.

Fibrinogen Mahdia: A congenitally abnormal fibrinogen characterized by defective fibrin polymerization.

Amri Y, Jouini H, Becheur M, Dabboubi R, Mahjoub B, Messaoud T, Sfar MT, Casini A, de Moerloose P, Toumi NEH.

Haemophilia. 2017 Jul;23(4):e340-e347. doi: 10.1111/hae.13268. Epub 2017 Jun 8.

PMID:
28594476
3.

Patient-derived anti-β2GP1 antibodies recognize a peptide motif pattern and not a specific sequence of residues.

de Moerloose P, Fickentscher C, Boehlen F, Tiercy JM, Kruithof EKO, Brandt KJ.

Haematologica. 2017 Aug;102(8):1324-1332. doi: 10.3324/haematol.2017.170381. Epub 2017 May 26.

4.

Protein modelling to understand FGB mutations leading to congenital hypofibrinogenaemia.

Casini A, Vilar R, Beauverd Y, Aslan D, Devreese K, Mondelaers V, Alberio L, Gubert C, de Moerloose P, Neerman-Arbez M.

Haemophilia. 2017 Jul;23(4):583-589. doi: 10.1111/hae.13190. Epub 2017 Mar 17.

PMID:
28306188
5.

Genetics, diagnosis and clinical features of congenital hypodysfibrinogenemia: a systematic literature review and report of a novel mutation.

Casini A, Brungs T, Lavenu-Bombled C, Vilar R, Neerman-Arbez M, de Moerloose P.

J Thromb Haemost. 2017 May;15(5):876-888. doi: 10.1111/jth.13655. Epub 2017 Mar 6.

PMID:
28211264
6.

Hypertension, haematuria and renal functioning in haemophilia - a cross-sectional study in Europe.

Holme PA, Combescure C, Tait RC, Berntorp E, Rauchensteiner S, de Moerloose P; ADVANCE Working Group.

Haemophilia. 2016 Mar;22(2):248-255. doi: 10.1111/hae.12847. Epub 2015 Dec 16.

PMID:
27880029
7.

A multicenter study to assess the reproducibility of antiphospholipid antibody results produced by an automated system.

Devreese KM, Poncet A, Lindhoff-Last E, Musial J, de Moerloose P, Fontana P.

J Thromb Haemost. 2017 Jan;15(1):91-95. doi: 10.1111/jth.13560. Epub 2016 Dec 18.

PMID:
27813343
8.

Outcome measures in European patients with haemophilia: Survey of implementation in routine clinical practice, perception of relevance and recommendations by European treaters in the EHTSB.

Hermans C, Klamroth R, Richards M, de Moerloose P, Garrido RP; EHTSB.

Haemophilia. 2017 Mar;23(2):222-229. doi: 10.1111/hae.13085. Epub 2016 Oct 27.

PMID:
27790841
9.

Management of congenital quantitative fibrinogen disorders: a Delphi consensus.

Casini A, de Moerloose P; Congenital Fibrinogen Disorders Group.

Haemophilia. 2016 Nov;22(6):898-905. doi: 10.1111/hae.13061. Epub 2016 Sep 19.

PMID:
27640400
10.

F-actin dampens NLRP3 inflammasome activity via Flightless-I and LRRFIP2.

Burger D, Fickentscher C, de Moerloose P, Brandt KJ.

Sci Rep. 2016 Jul 19;6:29834. doi: 10.1038/srep29834.

11.

Rare coagulation disorders: fibrinogen, factor VII and factor XIII.

de Moerloose P, Schved JF, Nugent D.

Haemophilia. 2016 Jul;22 Suppl 5:61-5. doi: 10.1111/hae.12965. Review.

PMID:
27405678
12.

Preoperative hemostatic assessment: a new and simple bleeding questionnaire.

Bonhomme F, Boehlen F, Clergue F, de Moerloose P.

Can J Anaesth. 2016 Sep;63(9):1007-15. doi: 10.1007/s12630-016-0688-9. Epub 2016 Jul 1.

PMID:
27369959
13.

Hypodysfibrinogenemia: A novel abnormal fibrinogen associated with bleeding and thrombotic complications.

Amri Y, Kallel C, Becheur M, Dabboubi R, Elloumi M, Belaaj H, Kammoun S, Messaoud T, de Moerloose P, Toumi Nel H.

Clin Chim Acta. 2016 Sep 1;460:55-62. doi: 10.1016/j.cca.2016.06.024. Epub 2016 Jun 22.

PMID:
27343352
14.

Can the phenotype of inherited fibrinogen disorders be predicted?

Casini A, de Moerloose P.

Haemophilia. 2016 Sep;22(5):667-75. doi: 10.1111/hae.12967. Epub 2016 Jun 13. Review.

PMID:
27293018
15.

The Role of Fibrinogen and Factor XIII in Hemostasis, and the Identification and Treatment of Associated Disorders.

Lisman T, de Moerloose P.

Semin Thromb Hemost. 2016 Jun;42(4):331-2. doi: 10.1055/s-0036-1579656. Epub 2016 May 27. Review. No abstract available.

PMID:
27232229
16.

Congenital afibrinogenemia: Identification and characterization of two novel homozygous fibrinogen Aα and Bβ chain mutations in two Tunisian families.

Amri Y, Toumi Nel H, Hadj Fredj S, de Moerloose P.

Thromb Res. 2016 Jul;143:11-6. doi: 10.1016/j.thromres.2016.04.016. Epub 2016 Apr 27.

PMID:
27164460
17.

Laboratory and Genetic Investigation of Mutations Accounting for Congenital Fibrinogen Disorders.

Neerman-Arbez M, de Moerloose P, Casini A.

Semin Thromb Hemost. 2016 Jun;42(4):356-65. doi: 10.1055/s-0036-1571340. Epub 2016 Mar 28. Review.

PMID:
27019463
18.

Clinical Features and Management of Congenital Fibrinogen Deficiencies.

Casini A, de Moerloose P, Neerman-Arbez M.

Semin Thromb Hemost. 2016 Jun;42(4):366-74. doi: 10.1055/s-0036-1571339. Epub 2016 Mar 28. Review.

PMID:
27019462
19.

Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study.

Marchetti T, de Moerloose P, Gris JC.

J Thromb Haemost. 2016 Apr;14(4):675-84. doi: 10.1111/jth.13257. Epub 2016 Mar 21.

PMID:
26782635
20.

Improving haemophilia patient care through sharing best practice.

de Moerloose P, Arnberg D, O'Mahony B, Colvin B.

Eur J Haematol. 2015 Oct;95 Suppl 79:1-8. doi: 10.1111/ejh.12630.

PMID:
26338268

Supplemental Content

Loading ...
Support Center